BioWorld

Dec. 31, 2002

View Archived Issues

SuperGen Starts Rolling NDA For Pancreatic Cancer Therapy

Coming in a few days under the wire, SuperGen Inc. said it has begun the rolling submission of a new drug application for Orathecin (rubitecan), an oral chemotherapy drug for refractory pancreatic cancer patients. (Bioworld Today) Read More

CV Therapeutics Submits NDA Seeking Approval Of Ranolazin

Read More

Applied Biosystems Cutting Work Force, Plans R&D Boost

Read More

Amphora Adds $23M In Series B To Carry Out Discovery Programs

Read More

Holiday Notice

Read More

Other News To Note

Read More